Familial hypercholesterolaemia| Volume 241, ISSUE 1, e109, July 2015

Is there a role for niacin in familial hypercholesterolaemia?

      Aim: Recent studies with extended release (ER) niacin in patients receiving intensive statin treatment with very low levels of low-density lipoprotein cholesterol (LDL-C) showed no benefit. In HPS2-THRIVE there was a trend for better outcomes in subgroups with higher baseline LDL-C or apolipoprotein (apo) B. We compared the lipid responses to ER niacin/ laropiprant in Chinese patients with and without familial hypercholesterolaemia (FH) to identify if those with higher baseline LDL-C might benefit.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect